阿卡替尼 Acalabrutinib Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity.

康奈非尼 Encorafenib Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity.

达帕菲尼 Dabrafenib Dabrafenib, also known as GSK2118436 , is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity.

维罗非尼 Vemurafenib Also known as PLX4032, RG7204 or RO5185426, is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity.

普纳替尼 Ponatinib Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities.

尼罗替尼 Nilotinib Nilotinib, also known as AMN107, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia.